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It has been shown recently that modification of peptidoglycan by O-acetylation renders pathogenic staphylococci
resistant to the muramidase activity of lysozyme. Here, we show that a Staphylococcus aureus double mutant defective
in O-acetyltransferase A (OatA), and the glycopeptide resistance-associated two-component system, GraRS, is much
more sensitive to lysozyme than S. aureus with the oatA mutation alone. The graRS single mutant was resistant to the
muramidase activity of lysozyme, but was sensitive to cationic antimicrobial peptides (CAMPs) such as the human
lysozyme-derived peptide 107R-A-W-V-A-W-R-N-R115 (LP9), polymyxin B, or gallidermin. A comparative transcriptome
analysis of wild type and the graRS mutant revealed that GraRS controls 248 genes. It up-regulates global regulators
(rot, sarS, or mgrA), various colonization factors, and exotoxin-encoding genes, as well as the ica and dlt operons. A
pronounced decrease in the expression of the latter two operons explains why the graRS mutant is also biofilm-
negative. The decrease of the dlt transcript in the graRS mutant correlates with a 46.7% decrease in the content of
esterified D-alanyl groups in teichoic acids. The oatA/dltA double mutant showed the highest sensitivity to lysozyme;
this mutant completely lacks teichoic acid–bound D-alanine esters, which are responsible for the increased
susceptibility to CAMPs and peptidoglycan O-acetylation. Our results demonstrate that resistance to lysozyme can
be dissected into genes mediating resistance to its muramidase activity (oatA) and genes mediating resistance to
CAMPs (graRS and dlt). The two lysozyme activities act synergistically, as the oatA/dltAo roatA/graRS double mutants
are much more susceptible to lysozyme than each of the single mutants.
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staphylococci. PLoS Pathog 3(7): e102. doi:10.1371/journal.ppat.0030102
Introduction
In humans, lysozyme is found in a wide variety of ﬂuids,
such as tears, breast milk, and respiratory and saliva
secretions, as well as in cells of the innate immune system,
including neutrophils, monocytes, macrophages, and epithe-
lial cells [1,2]. Lysozyme is an important protein in the innate
defense response against invading microorganisms and acts
on bacteria by hydrolyzing the ß-1,4 glycosidic bonds between
N-acetylmuramic acid (MurNAc) and N-acetylglucosamine
(GlucNAc), resulting in degradation of peptidoglycan (PG),
and subsequent cell lysis [3,4]. Most bacterial species are
sensitive to lysozyme, but some important human pathogens,
such as Staphylococcus aureus, Neisseria gonorrhoeae, and Proteus
mirabilis, are resistant. The mechanisms behind the high
resistance of S. aureus to lysozyme are unknown, although
several studies suggest that O-acetylation at position C-6 of
the MurNAc residue contributes to lysozyme resistance [5–9].
Recently, we were able to prove that indeed O-acetyltransfer-
ase A (OatA) of S. aureus is responsible for O-acetylation of the
PG, and this leads to resistance to the muramidase activity of
lysozyme [10]. We also showed that the MurNAc was O-
acetylated only in pathogenic, lysozyme-resistant staphylo-
cocci (e.g., S. aureus, S. epidermidis, S. lugdunensis, and others).
All nonpathogenic species (e.g., S. carnosus, S. gallinarum, or S.
xylosus) were lysozyme sensitive and lacked PG-speciﬁc O-
acetylation. Therefore, OatA can be regarded as a general
virulence factor [11].
Although the oatA mutant was less resistant to lysozyme
than the wild type (WT) S. aureus, it still was more resistant
than, for example, Micrococcus luteus, suggesting that other
factors, such as a high degree of peptide cross-linking, may
also contribute to lysozyme resistance [12]. Recently, we
showed that the presence of wall teichoic acid (WTA)
increased lysozyme resistance [13]. One also has to consider
that lysozyme does not only comprise muramidase activity
but also antimicrobial peptide activity, as demonstrated by
catalytically inactivate lysozyme or peptides isolated from
digested lysozyme, and by synthetic lysozyme-derived pep-
tides [14–17].
Here, we show that the extremely high resistance of S.
aureus to lysozyme can be genetically dissected as a) resistance
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antimicrobial peptide (CAMP) activity. Furthermore, we
characterized via transcriptome analysis the two-component
system (TCS), GraRS, which, in addition to many virulence
genes, also controls the dlt operon to mediate resistance to
lysozyme and other CAMPs.
Results
Susceptibility of oatA and graRS Single and Double
Mutants to Lysozyme and CAMPs
In our search for highly susceptible lysozyme mutants in S.
aureus, we isolated two Tn917 transposon mutants in
SA113oatA::kan that revealed higher sensitivity to lysozyme
than the oatA mutation alone. Chromosomal sequencing of
the ﬂanking Tn917 insertion sites revealed that Tn917 was
inserted in SA0615 [18]. SA0615 and the upstream gene
SA0614 have the features of a typical TCS and were recently
named GraRS (glycopeptide resistance-associated), because
overexpression of GraR (response regulator) and GraS
(sensor histidine kinase) increased vancomycin resistance
[19]. To further study the role of TCS in lysozyme resistance,
we constructed a deletion mutant by substituting graRS with
an erythromycin B cassette to yield SA113 graRS::erm (Figure
1). In addition, we also constructed an oatA::kan/graRS::erm
double knockout. Sequencing and complementation with
pTXgraRS, a vector in which the graRS genes are induced into
expression by xylose, conﬁrmed the correct replacement.
Whereas the oatA/graRS double mutant was highly susceptible
to lysozyme, both single mutants were only marginally
affected, but were still more sensitive than the WT, which is
completely lysozyme resistant (Figure 2A–2D).
The oatA/graRS double mutant was much more lysozyme
sensitive than each of the single mutants. This hyper-
sensitivity of the double mutant can be explained by dual
activities of lysozyme that act in a synergistic way. To study
this phenotype in more detail, we investigated whether the
graRS single mutant is affected by the muramidase activity of
lysozyme. Indeed, the isolated PG from the graRS single
mutant was completely resistant to lysozyme hydrolysis, in
contrast to the oatA mutant. As expected, PG of the oatA/
graRS double mutant was also hydrolysed, although the
sensitivity was less pronounced, as in the oatA single mutant
(Figure 3). Therefore, the increased sensitivity of the double
mutant likely came from its higher susceptibility to lysozyme’s
CAMP activity. This was conﬁrmed by the addition of LP9,
polymyxin B, or gallidermin to a growing culture, which
caused immediate growth arrest in the graRS mutant, whereas
the WT was much less affected (Figure 4A and 4B), and only
the lantibiotic gallidermin inhibited the WT. In addition, we
demonstrated that heat-inactivated lysozyme exhibits CAMP
activity, but no muramidase activity. Heat-inactivated lyso-
Figure 1. Illustration of Construction of the graRS Deletion Mutant
(A) Gene organization in the chromosome of WT SA113; Tn917 insertions in graS gene are indicated by arrows.
(B) In the graRS deletion mutant, graRS is substituted by the erythromycin B resistance cassette. Note that ermB gene has a weak transcription
terminator, and transcriptional read-through to the following vraFG genes is likely. graR, response regulator; graS, sensor histidine kinase; vraF, ABC
transporter ATP-binding protein; vraG, ABC transporter permease; SA0612 and SA0613 are hypothetical proteins (HP).
doi:10.1371/journal.ppat.0030102.g001
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Author Summary
In humans, lysozyme plays an important role in the suppression of
bacterial infections. However, some bacterial pathogens, such as
Staphylococcus aureus, are completely resistant to lysozyme. Here
we demonstrate that lysozyme acts on S. aureus in two ways: as a
muramidase (cell wall lytic enzyme) and as a cationic antimicrobial
peptide (CAMP). S. aureus has developed resistance mechanisms
against both activities by modifying distinct cell wall structures.
Modification of the peptidoglycan by O-acetylation (OatA) renders
the cells resistant to the muramidase activity. Modification of
teichoic acids by D-alanine esterification (Dlt) renders the cells
resistant to lysozyme’s CAMPs and other CAMPs. Transcriptome
analysis of the glycopeptide resistance-associated (GraRS) two-
component system revealed that this global regulator controls 248
genes such as other global regulators, colonization factors, or
exotoxin-encoding genes. Since GraRS also upregulates the dlt
operon, it was not surprising that in the graRS mutant teichoic acid
D-alanylation is markedly decreased, which explains its increased
sensitivity to CAMPs. By comparative analysis of mutants we were
able to dissect genes that were responsive to the dual activities of
lysozyme. Here we show how efficiently S. aureus is protected from
the human defense system, which enables this pathogen to cause
persistent infections.zyme showed no activity (neither lytic nor CAMP activity) to
the oatA mutant or to the isolated PG of oatA, but it was able
to inhibit the growth of the oatA/graRS double mutant
(Figures 2B, 2D, and 3). This result suggests that GraRS
controls genes involved in CAMP resistance. This effect was
not only achieved with hen egg-white, but also with human
lysozyme.
Comparative Transcriptome Analysis of WT and graRS
Mutant
To ﬁnd out which genes are responsible for the high
susceptibility to CAMPs in the graRS mutant, we carried out a
comparative transcriptome analysis of the WT strain and the
graRS mutant. We detected 115 genes whose mRNAs were up-
regulated (Table 1) and 133 genes whose mRNAs were down-
regulated by GraRS (Table 2). The complete list of up- and
down-regulated genes with their National Center for Bio-
technology Information PID numbers is presented in Dataset
S1. In order to give an impression of which genes are
controlled by GraRS, some examples are mentioned below.
In the graRS mutant, genes that are involved in RNA and
amino acid synthesis and glycolysis shows highly gene tran-
scription rates. In particular, the urease genes (ureA-G) all 12
pur genes were 2- to 32-fold up-regulated as compared to the
WT, whereas purR (repressor) appeared not to be inﬂuenced
by GraRS. Interestingly, the amount of oatA transcript
increased in the graRS mutant, which could explain the
slightly higher resistance of the graRS mutant to the
muramidase activity of lysozyme (Figure 3). A number of
genes that were down-regulated included global regulators
(rot, sarS, mgrA), cell surface protein encoding genes (the Ser-
Asp rich ﬁbrinogen-binding proteins SdrC and SdrE), the
major autolysin gene (atlA) and an autolysin/adhesin gene
(aaa) [20], exoprotein encoding genes (hlb, hlgA,B, lukM,F, and
geh), transporter encoding genes (essA/essC, oppB, and norB),
capsule encoding genes (capA,H,I,J,K) and PIA encoding genes
(icaADBC), genes responsible for D-alanyl esteriﬁcation of
teichoic acids (TAs) (dltA,B,D), and the alanine dehydrogenase
gene (ald1). The pronounced decrease of expression of the ica
[21–23] and dlt operons [24] and atlA [25] explains why the
graRS mutant showed a bioﬁlm-negative phenotype on
microtiter plates (unpublished data). With a few genes, such
as rot, ureC, and dltA, we veriﬁed the transcriptome data by
reverse transcriptase (RT)-PCR (Table 3).
Next, we asked which of the 115 less expressed genes in the
graRS mutant were responsible for the increased suscepti-
bility to CAMPs. A most likely candidate was the dlt operon
(encoding enzymes involved in D-alanylation of TAs). Its
transcript was decreased 2.1-fold to 2.9-fold as compared to
WT, and indeed, the D-alanylation of TAs was decreased
46.7% in the graRS mutant compared to WT (Table 3). It has
been previously shown that inactivation of the dlt operon in S.
aureus confers sensitivity to defensins, protegrins, and other
antimicrobial peptides [26]. The observed decrease of ald1
transcription by a factor of 3.5 is in line with the decreased dlt
transcription. Ald1 is the alanine dehydrogenase, which is
involved in the synthesis of L-alanine.
Comparison of graRS and dltA Mutants
Because the dlt operon is less expressed in the graRS
mutant, we investigated lysozyme susceptibility with a dltA
deletion mutant, which is well-known to be sensitive to
Figure 2. Susceptibility of WT SA113 and Various S. aureus Mutants to
Lysozyme and Heat-Inactivated Lysozyme
Cells were grown in BM at 37 8C. OD578nm was measured hourly for the
first 8 h and after 24 h. Lys was added in the exponential growth phase at
OD578nm 1.0 as indicated by arrow. Catalytic inactive Lys was heated for 1
h at 100 8C.
(A) WT SA113: control (*); Lys (300 lg/ml [20.8 lM]) ( ); heat-inactivated
lysozyme (Lys) (300 lg/ml [20.8 lM]) (&).
(B) oatA mutant: control (*); Lys (300 lg/ml) ( ); heat-inactivated Lys (300
lg/ml) (&).
(C) graRS mutant: control (*); Lys (300 lg/ml) ( ); heat-inactivated Lys
(300 lg/ml) (&).
(D) oatA/graRS mutant: control (*); Lys (50 lg/ml [3.47 lM]) ( ); heat-
inactivated Lys (300 lg/ml) (&).
(E) dltA mutant: control (*); Lys (300 lg/ml) ( ); heat-inactivated Lys (300
lg/ml) (&).
(F) oatA/dltA mutant: control (*); Lys (20 lg/ml [1.39 lM]) ( ); heat-
inactivated Lys (300 lg/ml) (&).
doi:10.1371/journal.ppat.0030102.g002
Figure 3. Susceptibility of PG Isolated from WT and Various Mutants to
Hydrolysis by Lysozyme
PG (0.5 mg/ml) isolated from WT SA113 and mutants were incubated
with catalytic active lysozyme (Lys); in addition, the oatA mutant was
incubated with heat-inactivated Lys (300 lg/ml) in 80 mM sodium
phosphate-buffered saline. Lysis of PG was measured as a decrease in
OD660nm and calculated in percent. The diagram shows 100% of PG in
the beginning (0 h) and the remaining undigested PG after 4 h of
lysozyme treatment.
doi:10.1371/journal.ppat.0030102.g003
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Lysozyme Resistance in Staphylococcus aureusCAMPs [26]. Indeed, the dltA mutant was more sensitive to
lysozyme (Figure 2E); however, this sensitivity was not due to
its muramidase activity, as the isolated PG of the dltA mutant
was not hydrolyzed by lysozyme (Figure 3). Furthermore,
growth of the dltA mutant was inhibited whether active or
heat-inactivated lysozyme was applied (Figure 2E). When the
susceptibility of graRS and dltA mutants to LP9, polymyxin B,
and gallidermin were compared, both mutants were similarly
more susceptible to these CAMPs (Figure 4B and 4C).
However, there were two distinctions: a) the susceptibility
of the dltA mutant was more pronounced than that of the
graRS mutant, and b) even in the presence of gallidermin or
polymyxin B, the graRS mutant started to grow after some
time and reached the same optical density (OD) values after
24 h as the control culture lacking CAMPs. In contrast, the
dltA mutant remained sensitive to gallidermin and polymyxin
B and was unable to resume growth. In the presence of LP9,
growth resumed after a similar lag period as in the graRS
mutant; this can possibly be explained by its proteolytic
degradation. Not only the single but also the double mutants
oatA/graRS and oatA/dltA were sensitive to the CAMP activity
of LP9, although the susceptibility was less pronounced as
with the graRS and dltA single mutants. However, the oatA
single mutant was completely resistant to LP9, indicating that
oatA is resistant to CAMPs (Figure 4D–4F). With respect to
gallidermin- and polymyxin B–induced cell lysis, it has been
observed that CAMPs such as lantibiotics induce autolysis in
staphylococci by increasing PG hydrolase activity [27]. We
assume that gallidermin and polymyxin B, which are also
CAMPs, very likely have a similar effect.
We asked whether the increasing insensitivity of the graRS
mutant after prolonged growth is some short lasting CAMP-
induced adaptation or whether it is based on selection of
resistant mutants. To answer this question, we inoculated
from a 24-h graRS culture treated with polymyxin B (Figure
5B) a new culture and challenged it again with polymyxin B
(Figure 5C). The subculture revealed no growth retardation,
which suggests that the graRS phenotype is unstable and that
polymyxin B–resistant revertants were quickly selected. Since
the dltA revealed a stable phenotype, we assume that in the
selected revertants dltA expression was increased to WT levels.
Hypersensitivity of the oatA/dltA and oatA/graRS Double
Mutants to Lysozyme
The highest susceptibility to lysozyme was observed with
the oatA/dltA double mutant, which was more than 66-fold
and 333-fold more sensitive to lysozyme than the dltA and
oatA single mutants, respectively (Figure 2B, 2E, and 2F; Table
4). The oatA/graRS mutant is not quite as sensitive as the oatA/
dltA mutant. Another difference is that the oatA/dltA mutant
stays lysozyme sensitive even after 24 h of cultivation (Figure
2D and 2F), indicating that the dltA mutant phenotype cannot
easily revert to the WT phenotype. The lower susceptibility of
the oatA/graRS double mutant can possibly be explained by
the fact that the TA in this mutant still contains 53.3% D-
alanyl esters, whereas the dltA mutant completely lacks D-
alanylation in its TAs (Table 3).
The high susceptibility of the double mutants is based on
the dual activities of lysozyme: a) the oatA mutant is sensitive
to the muramidase activity of lysozyme but is insensitive to
CAMPs (Figures 2B, 3, and 4F), and b) the dltA and graRS
mutants are sensitive to CAMPs, but insensitive to the
muramidase activity of lysozyme (Figures 3, 4B, and 4C).
The extremely high lysozyme susceptibility of the oatA/dltA
double mutant can only be explained by a synergistic effect of
the two activities.
Increased Lytic Activity of Mutanolysin by Lysozyme and
LP9 in the graRS Mutant
Mutanolysin is a muramidase that is able to hydrolyze O-
acetylated PG [28] but does not normally cause cell lysis in
WT S. aureus or its graRS mutant at a concentration of 100 lg/
ml. However, when the graRS mutant was treated with
mutanolysin in combination with lysozyme or LP9, the lytic
activity (indicated by decrease in OD) was strongly increased
(Figure 5A). Because the O-acetylated graRS mutant is
insensitive to the catalytic activity of lysozyme, we assume
that mutanolysin acts through its lytic activity, and LP9 and
lysozyme through their CAMP properties. We have not
investigated how the stimulating effect of lysozyme and LP9
on cell lysis is accomplished. However, we assume that it is
caused by the concerted action of PG hydrolysis by
mutanolysin and induced autolysis by lysozyme and LP9, as
mentioned above.
Minimal Inhibition Concentration Values of SA113 and
Various Mutants
The minimal inhibition concentration (MIC) values for
lysozyme, polymyxin B, and gallidermin in WT and various
mutants are summarized in Table 4. Both the WT and the
Figure 4. Susceptibility of WT and Various S. aureus Mutants to CAMPs
(A) WT SA113: control (*); LP9 (200 lg/ml [164.9 lM]) (u); polymyxin B
(PMB) (20 lg/ml [14.4 lM]) (&); and gallidermin (Gdm) (8 lg/ml [3.64 lM])
(m).
(B) graRS mutant: control (*); LP9 (200 lg/ml) (u); PMB (20 lg/ml) (&); and
Gdm (8 lg/ml) (m).
(C) dltA mutant: control (*); LP9 (200 lg/ml) (u); PMB (20 lg/ml) (&); and
Gdm (8 lg/ml) (m).
(D) oatA/graRS mutant: control (*); LP9 (200 lg/ml) (u).
(E) oatA/dltA mutant: control (*); LP9 (200 lg/ml) (u).
(F) oatA mutant: control (*); LP9 (200 lg/ml) (u).
Cells were grown in BM at 37 8C. OD578nm was measured hourly for the
first 7–8 h and after 24 h. CAMPs were added in the exponential growth
phase at OD578nm 1.0 as indicated by arrow.
doi:10.1371/journal.ppat.0030102.g004
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Lysozyme Resistance in Staphylococcus aureusTable 1. 115 S. aureus SA113 Genes Up-Regulated by GraRS
Function of Proteins N315
ORF
N315
Gene
N315 Product Protein
Location
Change in
Expression
(n-Fold)
One-Sample
t-Test-Benjamini–
Hochberg (Adv)
rot, mgrA,
arlRS Effect
Virulence factors (cell
surface proteins,
exotoxins, colonization
factors)
SA0519 sdrC Ser-Asp rich fibrinogen-binding, bone
sialoprotein-binding protein
SCW 9.6 0.013 rot, arl up
SA0521 sdrE Ser-Asp rich fibrinogen-binding, bone
sialoprotein-binding protein
SCW 2.9 0.034 mgr, arl up
SA1003 fib HP, similar to fibrinogen-binding protein SCW 2.5 0.036
SA1004 HP, similar to fibrinogen-binding protein SCW 2.2 0.164 mgr down
SA0222 coa Staphylocoagulase precursor S 2.1 0.013 rot up
SA0309 geh Glycerol ester hydrolase, lipase 2 S 2.2 0.012 rot down
SA1811 hlb Truncated beta-hemolysin S 2.2 0.007 rot down
SA1812 lukM Leukocidin chainLukM S 2.5 0.042 rot down, mgr up
SA1813 lukF Synergohymentropic toxin precursor S 2.1 0.010 mgr up
SA2207 hlgA Gamma-hemolysin component A S 2.1 0.010 mgr up
SA2209 hlgB Gamma-hemolysin component B S 2.1 0.005 rot, arl down
SA0270 HP, similar to secretory antigen precursor SsaA S 2.9 0.012 arl up
SA0271 esxA Virulence factor EsxA S 4.4 0.012 rot, arl up
SA0620 HP, similar to secretory antigen precursor SsaA S 2.1 0.013 rot up
SA2097 HP, similar to secretory antigen precursor SsaA S 3.0 0.014
SA2431 isaB Immunodominant antigen B S 2.2 0.022 mgr down
SA2459 icaA Intercellular adhesion protein A M 4.8 0.032
SA2460 icaD Intercellular adhesion protein D M 4.9 0.006
SA2461 icaB Intercellular adhesion protein B SCW 3.3 0.063
SA2462 icaC Intercellular adhesion protein C M 2.5 0.068
Regulators SA0108 sarS Staphylococcal accessory regulator A homolog C 7.2 0.007 rot up, mgr down
SA0614 graR C 3.1 0.062
SA0641 mgrA HTH-type transcriptional regulator
MgrA, MarR family
C 3.1 0.007
SA0856 spxA Transcriptional regulator Spx C 5.6 0.024
SA1583 rot Repressor of toxins Rot C 3.8 0.009 arl up
SA1678 furB Transcriptional regulator Fur family homolog C 2.1 0.023 mgr up
SA2174 HP, similar to transcriptional regulator C 2.0 0.046
Cell wall (cellular processes,
transport, membrane,
lipoproteins, autolysins)
SA0106 lctP Lactate transporter, LctP family M 3.2 0.021
SA0109 sirC Lipoprotein M 3.5 0.013
SA0111 sirA Lipoprotein M 2.0 0.086
SA0138 HP, similar to alkylphosphonate ABC transporter M 2.1 0.004 arl down
SA0204 azoR FMN-dependent NADH-azoreductase C 2.2 0.021
SA0207 HP, similar to maltose/maltodextrin-binding
protein
M 2.1 0.035
SA0208 Maltose/maltodextrin transport
permease homolog
M 2.1 0.064
SA0268 HP, similar to ABC transporter system
permease protein
M 2.3 0.007
SA0272 esaA Protein EsaA M 4.7 0.022 arl up
SA0273 essA Protein EssA M 2.8 0.071
SA0276 essC Protein EssC M 2.6 0.027 arl up
SA0295 HP, similar to outer membraneprotein precursor M 2.3 0.010
SA0423 aaa N-acetylmuramoyl-L-alanine amidase SCW 3.6 0.015
SA0518 azo1 FMN-dependent NADPH-azoreductase C 2.1 0.019
SA0793 dltA D-alanine-D-alanyl carrier protein ligase C 2.9 0.066
SA0794 dltB DltB membrane protein M 2.1 0.010
SA0796 dltD Poly (glycerophosphate chain) D-alanine
transfer protein
M 2.3 0.008 rot up
SA0845 oppB Oligopeptide transport system permease protein M 2.2 0.039
SA0846 HP, similar to oligopeptide transport system
permease protein OppC
M 2.1 0.049
SA0849 HP, similar to peptide binding protein OppA M 2.4 0.030 mgr down
SA0854 HP, similar to oligopeptide transport system
permease protein OppC
M 2.1 0.053
SA0905 atlA Autolysin (N-acetylmuramoyl-L-alanine
amidase/endo-beta-N-acetylglucosaminidase
SCW 2.4 0.015
SA1269 norB Blt-like protein, efflux pump M 3.6 0.004 mgr, arl up
SA1270 HP, similar to acid permease M 3.5 0.012 mgr, arl up
SA1663 HP, belongs to the UPF0342 protein family M 2.3 0.072
SA1979 HP, similar to ferrichrome ABC transporter M 2.1 0.032
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Function of Proteins N315
ORF
N315
Gene
N315 Product Protein
Location
Change in
Expression
(n-Fold)
One-Sample
t-Test-Benjamini–
Hochberg (Adv)
rot, mgrA,
arlRS Effect
SA2156 L-lactate permease IctP homolog M 3.7 0.015
SA2217 HP, similar to lipoprotein inner membrane
ABC transporter
M 2.1 0.022
SA2302 stpC HP, similar to ABC transporter M 3.1 0.008 mgr up
SA2303 smpC HP, similar to membrane spanning protein M 5.5 0.010 rot, mgr, arl up
SA2475 HP, belongs to ABC-transporter M 2.3 0.067
SA2477 HP, belongs to the UPF0397 protein family M 2.3 0.068
SA2480 drp35 Lactonase Drp35 C 2.3 0.036
Adaptation to
stress conditions
SA2457 capA Capsular polysaccharide biosynthesis, capA M 2.0 0.008 arl down
SA0151 capH Capsular polysaccharide synthesis enzyme
O-acetyltransferase Cap5H
M 2.0 0.033 mgr up
SA0152 capI Capsular polysaccharide synthesis enzyme Cap5I M 2.0 0.034 mgr up
SA0153 capJ Capsular polysaccharide synthesis enzyme Cap5J M 2.3 0.084 mgr up
SA0154 capK Capsular polysaccharide synthesis enzyme Cap5K M 2.7 0.025 mgr up
SA1984 asp23 Alkaline shock protein 23, ASP23 C 2.1 0.082
Others (RNA, DNA,
carbohydrates,
amino acids, protein,
lipid synthesis)
SA0515 HP, similar to deoxypurine kinase C 2.1 0.014
SA1013 HP, similar to carbamate kinase C 2.3 0.023
SA0143 adhE Alcohol-acetaldehyde dehydrogenase C 2.0 0.008 rot down
SA0180 Branched-chain amino acid:cation transporter M 2.0 0.010
SA1225 lysC Aspartokinase II C 2.1 0.015
SA1271 Threonine deaminase IlvA homolog C 2.7 0.077 arl up
SA1272 ald1 Alanine dehydrogenase C 3.5 0.007 mgr, arl up
SA1502 rplT 50S ribosomal protein L20 C 2.1 0.060
SA0220 HP, similar to glycerophosphodiester
phosphodiesterase
C 2.1 0.008 rot, arl up
SA0027 Truncated replication protein for plasmid 3.6 0.096
SA1709 HP, similar to ferritin 2.6 0.034
Phage-related functions SA1760 Holin homolog (bacteriophage phiN315) M 2.4 0.104
SA1766 HP (bacteriophage phiN315) 6.0 0.087
SA1785 HP (bacteriophage phiN315) 2.5 0.028
SA1793 HP (bacteriophage phiN315) 23.3 0.074
Hypothetical genes SA0037 HP 3.4 0.062
SA0077 HP 3.8 0.073
SA0081 HP 2.3 0.041
SA0090 HP 6.4 0.089 mgr up
SA0100 HP 2.8 0.008
SA0161 HP 2.0 0.075
SA0213 HP 2.4 0.014
SA0221 HP 2.2 0.062 mgr down
SA0262 HP 2.3 0.062
SA0279 HP 2.2 0.005 mgr up
SA0283 HP 2.3 0.042
SA0291 HP 3.3 0.068 rot, mgr up
SA0292 HP 3.9 0.030 rot up
SA0378 HP 3.5 0.021
SA0408 HP 2.7 0.048 rot up
SA0424 HP 2.4 0.038
SA0623 HP 2.8 0.059
SA0651 HP 3.1 0.027 rot up
SA0738 HP 5.5 0.058
SA0739 HP 4.7 0.010 rot up
SA0772 HP 2.1 0.096
SA0890 HP 3.4 0.012
SA1056 HP M 3.4 0.012
SA1151 HP 2.1 0.022
SA1828 HP 2.2 0.040
SA2101 HP 2.6 0.012
SA2153 HP 2.2 0.010
SA2198 HP 2.1 0.062
SA2256 HP 2.2 0.040
SA2332 HP 2.4 0.019
SA2339 HP M 4.5 0.012
SA2373 HP 2.2 0.034 mgr down
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Lysozyme Resistance in Staphylococcus aureusgraRS mutant were completely resistant to lysozyme at a
concentration of 50 mg/ml. However, the graRS mutant was
17- and 4-fold more susceptible to polymyxin B or gallider-
min. The sensitivity to the CAMPs is very likely due to the
aforementioned decrease in expression of the dlt operon,
which corresponds with decreased D-alanylation of the TAs.
The oatA mutant was more susceptible to lysozyme than the
graRS mutant, but, similar to WT, was completely insensitive
to heat-inactivated lysozyme or CAMPs, indicating that oatAi s
only sensitive to the muramidase activity of lysozyme. The
oatA/graRS double mutant was almost 17-fold more sensitive
to lysozyme than the oatA mutant, which can be explained by
the fact that this double mutant is sensitive to both the
muramidase and the CAMP activities of lysozyme. The two
activities exert a synergistic effect on the double mutant. The
dltA single mutant was over 25-fold more sensitive to
lysozyme than the WT and 5-fold more sensitive than the
oatA single mutant, demonstrating the importance of
lysozyme’s CAMP activity. Furthermore, the dltA mutant
exhibited the highest susceptibility to polymyxin B and
gallidermin, but was completely insensitive to lysozyme’s
muramidase activity (Figure 3).
With a MIC of only 30 lg/ml, the oatA/dltA double mutant
revealed the highest susceptibility to lysozyme. Indeed, it has
a 20-fold greater sensitivity to lysozyme than the oatA/graRS
double mutant. The oatA/dltA double mutant is 333-fold and
66-fold more sensitive than the single oatAo rdltA mutants,
which illustrates the extremely high synergistic effect of
lysozyme when it can exert both muramidase and CAMP
activities. Overexpression of graRS in the graRS mutant or the
WT by pTXgraRS resulted in an approximately 2-fold
increase in polymyxin B resistance, indicating that even in
WT cells, CAMP resistance can be further increased.
Discussion
One of our research aims was to identify genes involved in
staphylococcal lysozyme resistance. We have already eluci-
dated two genes and corresponding enzymes that contribute
to resistance against the muramidase activity of lysozyme.
Since the target of muramidase is PG, it is not surprising that
the mechanism of resistance is masking PG by modiﬁcation.
In S. aureus there are two PG modiﬁcations that are involved
in resistance to lysozyme’s muramidase activity. One mod-
iﬁcation is O-acetylation catalyzed by the PG-speciﬁc O-
acetyltransferase A, OatA, and we have shown that the oatA
mutant is more susceptible to the muramidase activity of
lysozyme than the WT [10]. The other modiﬁcation is WTA
[29] that is covalently linked to the same C6 position in
MurNAc as in the O-acetyl group. TagO is a speciﬁc UDP-N-
acetylglucoseamine transferase, which is involved in the ﬁrst
step of WTA synthesis. The tagO deletion mutant completely
lacks WTA [30]. Although the tagO mutant still shows high
lysozyme resistance, a oatA/tagO double mutant, however, is
much more susceptible to lysozyme’s muramidase activity
than the oatA mutation alone [13]. Here, we show that the
high lysozyme resistance of S. aureus is not only based on
resistance to the muramidase activity of lysozyme, but also to
its inherent CAMP resistance.
The described global two-component regulator, GraRS, was
identiﬁed in an oatA-minus background by increased lyso-
zyme susceptibility in an oatA/graRS double mutant. The
graRS mutant was more susceptible to CAMPs than the WT.
We assume that the reason for the increased susceptibility of
the graRS mutant was a decrease in dlt expression, and
consequently, GraRS up-regulates dlt expression. The Dlt
enzymes modify TAs by the incorporation of D-alanine esters
rendering the cells resistant to CAMPs, very likely by
repulsion [26]. We showed that the dltA mutant is even more
susceptible to lysozyme-derived LP9 and other CAMPs than
the graRS mutant, because in the dltA mutant, D-alanine esters
were completely absent in TAs, the mutant was stable, and no
revertants were observed. Heat-inactivated lysozyme does not
affect either the growth of the oatA or that of the graRS
mutant. The latter effect is surprising, as the graRS mutant is
sensitive to the other CAMPs (LP9, gallidermin, polymyxin B).
However, the oatA/graRS mutant was sensitive to heat-
inactivated lysozyme, suggesting that the bulky molecule has
better access to the cell envelope when the PG is de-O-
acetylated. Likewise, sensitivity of the dltA mutant to heat-
inactivated lysozyme can also be explained by better access to
the cell envelope because of the lack of D-alanine esters in
TAs.
The next interesting question was, how do CAMPs act in
the dltA, oatA/graRS, or oatA/dltA mutants? Killing of Gram-
negative bacteria could be demonstrated by lysozyme-derived
peptides that were transported through the outer membrane
and damaged the inner membrane by pore formation [17].
Several authors assume that lysozyme and CAMPs are not
only acting as membrane permeabilization agents, but also
activate autolytic wall enzymes of Gram-positive bacteria,
thus causing cell lysis [31–33]. It has also been shown that
lipoteichoic acids can bind and inhibit autolysins, depending
on their degree of D-alanylation [34–36]. Similar results were
also obtained in a dlt mutant of Lactococcus lactis, which showed
increased autolysis [37]. In line with these observations, the
Table 1. Continued.
Function of Proteins N315
ORF
N315
Gene
N315 Product Protein
Location
Change in
Expression
(n-Fold)
One-Sample
t-Test-Benjamini–
Hochberg (Adv)
rot, mgrA,
arlRS Effect
SA2449 HP 2.4 0.060
SA2474 HP 2.1 0.076
C, cytoplasm; HP, hypothetical protein; M, membrane; S, secreted; SCW, secreted cell wall–bound.
doi:10.1371/journal.ppat.0030102.t001
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Lysozyme Resistance in Staphylococcus aureusTable 2. 133 S. aureus SA113 Genes Down-Regulated by GraRS
Function
of Proteins
N315
ORF
N315
Gene
N315 Product Protein
Location
Change in
Expression
(n-Fold)
One-Sample
t-Test-
Benjamini–
Hochberg (Adv)
rot, mgrA,
arlRS Effect
Regulators SA0017 vicR Response regulator C 2.0 0.004
SA1071 fabR Transcription factor FapR C 2.3 0.015
SA1690 recX Regulatory protein RecX C 2.0 0.021
SA2296 HP, similar to transcriptional regulator, MerR family C 2.1 0.012
SA2320 pfoR Putative regulatory protein PfoR M 5.7 0.010 mgr, arl down
SA2418 HP, similar to two-component response regulator C 2.1 0.007
Cell wall (cellular
processes, transport,
membrane,
lipoproteins)
SA0252 lrgA Holin-like protein LrgA M 2.6 0.017 mgr, arl up
SA0469 ftsH Cell-division protein M 2.2 0.004
SA0616
a vraF ABC transporter ATP-binding protein M 8.6 0.005
SA0617
a vraG ABC transporter permease M 4.8 0.029
SA0708 secA Preprotein translocase subunit M 2.1 0.012
SA0719 trxB Thioredoxine reductase M 2.5 0.016
SA0937 Cytochrome D ubiquinol oxidase subunit 1 homolog M 2.5 0.010
SA0997 murl Glutamate racemase C 2.4 0.009
SA1127 cinA Competence-damage inducible protein CinA C 2.0 0.024
SA1140 glpF Gycerol uptake facilitator M 2.2 0.014
SA1206 femA Aminoacyltransferase femA (factor essential for
expression of methicillin resistance)
M 2.0 0.006
SA1212 opp-2D Oligopeptide transport ATPase M 2.2 0.032
SA1214 opp-2B Oligopeptide transporter membrane
permease domain
M 2.5 0.036
SA1255 crr Glucose-specific phosphotransferase enzyme
IIA component
M 2.2 0.011
SA1519 aapA D-serine/ D-alanine/glycine TRANSPORTER M 2.4 0.004
SA1653 TRAP Signal transduction protein TRAP M 2.4 0.005
SA1654 HP, similar to ABC transporter ecsB M 2.5 0.015
SA1655 ABC transporter ecsA homolog M 2.3 0.012
SA1916 HP, belongs to the UPF0340 protein family M 2.4 0.063
SA1960 mtlF PTS system, mannitol specific IIBC component M 2.2 0.040 mgr down
SA2056 HP, similar to acriflavin resistance protein M 2.0 0.010
SA2234 oupCD Probable glycine betaine/carnitine/choline ABC
transporter opuCD
M 2.3 0.025
SA2324 HP, similar to thioredoxin M 2.2 0.015
SA2354 oatA O-acetyltransferase A M 2.5 0.012
RNA (nucleotides,
nucleic acid
synthesis,
regulation)
SA0016 purA Adenylosuccinate synthase C 2.2 0.019 mgr down
SA1724 purB Adenylosuccinate lyase C 2.6 0.004 mgr up
SA0133 deoC1 Deoxyribose-phosphate aldolase C 2.8 0.005
SA0134 deoB Phosphopentomutase C 2.7 0.041
SA0915 folD FolD bifunctional protein C 6.0 0.004
SA0916 purE Putative phosphoribosylaminoimidazole
carboxylase PurE
C 19.4 0.005
SA0917 purK Phosphoribosylaminoimidazole carboxylase
ATPase subunit
C 22.2 0.007
SA0918 purC Phosphoribosylaminoimidazole-succinocarboxamide
synthase
C 14.2 0.010
SA0920 purQ Phosphoribosylformylglycinamidine synthase I PurQ C 19.9 0.007
SA0921 purL Phosphoribosylformylglycinamidine synthetase PurL C 13.8 0.009
SA0922 purF Phosphoribosylpyrophosphate amidotransferase PurF C 28.7 0.004
SA0923 purM Phosphoribosylformylglycinamidine cyclo-ligase PurM C 21.6 0.006 rot up
SA0924 purN Phosphoribosylglycinamide formyltransferase C 25.5 0.004
SA0925 purH Bifunctional purine biosynthesis protein PurH C 17.7 0.004
SA0926 purD Phosphoribosylamine-glycine ligase PurD C 8.1 0.004
SA1172 HP, similar toGMP reductase C 4.3 0.008
SA1237 xpaC HP, similar to 5-bromo-4-chloroindolyl phosphate
hydrolysis protein
C 2.0 0.008
SA1914 upp Uracil phosphoribosyl transferase C 2.3 0.014
SA1938 pdp Pyrimidine nucleoside phosphorylase C 2.1 0.010
SA1939 Deoxyribose-phosphate aldolase C 2.5 0.014
SA1098 codY Transcription pleiotropic repressor CodY C 2.2 0.072
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Function
of Proteins
N315
ORF
N315
Gene
N315 Product Protein
Location
Change in
Expression
(n-Fold)
One-Sample
t-Test-
Benjamini–
Hochberg (Adv)
rot, mgrA,
arlRS Effect
SA1289 Putative bifunctional biotin ligase/biotin
operon repressor
C 2.1 0.004
SA1411 hrcA Heat-inducible transcriptional repressor C 2.2 0.010
SA2410 nrdD Anaerobic ribonucleoside-triphosphate reductase C 4.5 0.004 rot up
Adaptation to
stress conditions
SA0470 hslO Heat-shock protein HSP33 homolog C 2.1 0.009
SA0480 ctsR Transcription repressor of class III stress
genes homolog
C 2.3 0.010
SA0509 hchA Molecular chaperoneHchA C 2.5 0.012
SA1096 clpQ Heat shock protein HslV C 2.5 0.004
SA1238 HP, similar to tellurite resistance protein C 2.5 0.009
SA1408 dnaJ DnaJ protein (HSP40) C 2.9 0.006
SA1409 dnaK DnaK protein C 2.4 0.012
SA1410 grpE GrpE protein (HSP-70 cofactor HSP20) C 2.6 0.021
SA1535 tpx HP, similar to thioredoxin peroxidase C 2.5 0.021
Carbohydrate
mechanism
SA0728 pgk Phosphoglycerate kinase C 2.2 0.016
SA0729 tpiA Triosephosphate isomerase C 2.1 0.065
SA0730 gpml 2,3-diphosphoglycerate-independent
phosphoglycerate mutase
C 2.0 0.029
SA0731 eno Enolase (2-phosphoglycerate dehydrogenase) C 2.1 0.010
SA0958 Putative myo-inositol-1 (or 4)-monophosphatase C 2.0 0.006
SA1088 sucC Succinyl-CoA synthetase, beta chain C 3.9 0.004
SA1089 sucD Succinyl-CoA synthetase, alpha chain C 3.2 0.004
SA1184 acnA Aconitate hydratase C 2.5 0.010
SA1336 Glucose-6-phosphate 1-dehydrogenase C 2.2 0.012
SA1517 citC Isocitrate dehyrogenase C 2.2 0.015
SA1518 citZ Citrate synthase II C 2.4 0.019
SA1553 fhs Formyltetrahydrofolate synthetase C 2.2 0.030
SA1996 lacB Galactose-6-phosphate isomerase LacB subunit C 2.4 0.025 mgr, arl down
SA2001 HP, similar to oxidoreductase, aldo/ketoreductase family C 2.3 0.034 rot up
SA2008 alsS Alpha-acetolactate synthase C 2.9 0.004 mgr, arl down
SA2304 fbp Fructose-bisphosphatase C 2.1 0.010
SA2312 ddh D-specific D-2-hydroxyacid dehydrogenase C 2.5 0.071 rot, mgr down
Amino acid synthesis SA0822 argG Argininosuccinate synthase C 2.0 0.012
SA0829 HP, similar to 5-oxo-1,2,5-tricarboxillic-3-
penten acid decarboxylase
C 2.1 0.025
SA0859 Thimet oligopeptidase homolog C 2.6 0.014
SA1347 bfmBAB Branched-chain alpha-keto acid dehydrogenase E1 C 2.1 0.010
SA1365 gevPB glycine dehydrogenase (decarboxylating)
subunit 2 homolog
C 2.7 0.010
SA1366 gevPA glycine dehydrogenase (decarboxylating) subunit 1 C 3.9 0.004
SA1367 gcvT Aminomethyltransferase C 3.6 0.004
SA1915 glyA Serine hydroxymethyl transferase C 2.3 0.008
SA2081 Urea transporter M 5.5 0.010 mgr, arl down
SA2082 ureA Urease gamma subunit C 13.1 0.009 rot, mgr, arl down
SA2083 ureB Urease beta subunit C 32.4 0.006 rot, mgr, arl down
SA2084 ureC Urease alpha subunit C 24.9 0.007 rot, mgr, arl down
SA2085 ureE Urease accessory protein UreE C 16.0 0.089 rot, mgr, arl down
SA2086 ureF Urease accessory protein UreF C 23.7 0.004 rot, mgr, arl down
SA2087 ureG Urease accessory protein UreG C 21.4 0.012 rot, mgr, arl down
SA2088 ureD Urease accessory protein UreD C 10.0 0.007 rot, mgr, arl down
SA2318 sdhA Putative L-serine dehydratase C 3.7 0.010 mgr down
SA2319 sdhB Putative beta-subunit of L-serine dehydratase C 2.5 0.071 mgr, arl down
Others (lipid
synthesis, DNA
repair, coenzyme)
SA0842 fabH 3-oxoacyl-(acyl-carrier protein) synthase 3 C 2.4 0.063
SA1072 plsX Fatty acid/phospholipid synthesis protein C 2.7 0.006
SA1073 fabD Malonyl CoA-acyl carrier protein transacylase C 2.8 0.011
SA1074 fabG 3-oxoacyl-reductase, (acyl-carrier protein) reductase C 2.7 0.006
SA0484 radA DNA repair protein homolog C 2.0 0.096
SA1138 mutL DNA mismatch repair protein C 2.1 0.026
SA1512 HP, similar to formamidopyrimidine-DNA glycosylase C 2.0 0.012
SA0831 cdr Coenzyme A disulfide reductase C 2.1 0.009
SA0231 HP, similar to flavohemoprotein C 2.4 0.011
SA0998 HAM1 protein homolog M 2.4 0.013
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Lysozyme Resistance in Staphylococcus aureusgraRS and dltA mutants also showed increased autolysis when
treated with Triton X-100 (unpublished data), suggesting that
in these mutants, too, CAMPs activate autolytic enzymes. We
assume that the observed synergistic effect of lysozyme in the
oatA/graRS and oatA/dltA double mutants is caused by the
simultaneous activation of autolytic enzymes and the mur-
amidase activity of lysozyme. A similar synergistic effect is
seen by treatment with mutanolysin in combination with LP9
(inducing autolysis) or lysozyme (cannot exert its muramidase
activity as the PG is O-acetylated) as shown in the graRS single
mutant (Figure 5A). For the ﬁrst time (to our knowledge), we
have traced and dissected genes that were responsive to the
dual activities of lysozyme.
Until now, little was known about the two-component
system GraRS. We became interested in the regulation of
GraRS because we wanted to trace the gene(s) that caused the
increased CAMP susceptibility in the graRS mutant. Com-
parative transcriptome analysis of SA113, an 8325-derivative,
and its graRS mutant revealed that 115 genes were up-
regulated and 133 genes were down-regulated by GraRS
(Tables 1 and 2). Among the down-regulated genes was the
vraFG operon, which immediately follows the graRS operon.
However, in studying intermediate level of vancomycin
resistance in S. aureus, Ambrose Cheung and colleagues found
that vraFG is positively controlled by GraRS [38]. This
contradictory result can be explained by the genetic
organization of our graRS::ermB deletion mutant (Figure 1).
In our mutant, the ermB cassette is in the same orientation as
the vraFG genes. Since the ermB transcription terminator is
very weak, we assume that there is a transcriptional read-
through into the vraFG genes. This explains why in our graRS
deletion mutant, the vraFG genes were up-regulated instead
of down-regulated.
GraRS up-regulates transcription of global regulators such
as the SarA homologs Rot, SarS, and MgrA. We compared our
GraRS transcriptome results with that of the recently
published transcriptome studies of Rot [39], MgrA [40], and
ArlRS [41] (Tables 1 and 2; Figure 6). Rot is a repressor of
exoproteins but positively regulates cell surface proteins, and
SarS is a positive activator of protein A. MgrA appears to be
Table 2. Continued.
Function
of Proteins
N315
ORF
N315
Gene
N315 Product Protein
Location
Change in
Expression
(n-Fold)
One-Sample
t-Test-
Benjamini–
Hochberg (Adv)
rot, mgrA,
arlRS Effect
SA1105 Putative zinc metalloprotease 2.1 0.005
SA1312 ebpS Elastin binding protein 2.9 0.038
SA1349 Dihydrolipoamide dehydrogenase C 2.1 0.011
SA2301 HP, similar to GTP-pyrophosphokinase 2.8 0.010
Hypothetical genes SA0175 HP 3.6 0.014
SA0381 HP 2.7 0.019
SA0427 HP 2.2 0.012 mgr up
SA0481 HP C 2.0 0.008
SA0558 HP 2.1 0.004
SA0804 HP 5.5 0.008
SA0805 HP 4.8 0.004
SA0832 HP 2.4 0.007
SA0833 HP 2.1 0.024
SA0860 HP 2.5 0.037
SA0903 HP 2.1 0.014
SA1173 HP 2.6 0.004
SA1280 HP, conserved 2.0 0.012
SA1534 HP 2.4 0.007
SA1723 HP C 3.2 0.016
SA1937 HP 2.2 0.010
SA2005 HP 2.3 0.023
SA2050 HP 2.2 0.017
SA2138 HP 2.4 0.045
SA2160 HP 2.3 0.011
SA2297 HP 2.3 0.016 rot down
avraFG were down-regulated instead of up-regulated because of transcriptional read-through into the vraFG genes by the very weak ermB transcription terminator.
C, cytoplasm; HP, hypothetical protein; M, membrane; S, secreted; SCW, secreted cell wall–bound.
doi:10.1371/journal.ppat.0030102.t002
Table 3. RT-PCR Values and D-Alanylation of TAs
Strains RT-PCR
rot (%)
RT-PCR
ureC (%)
RT-PCR
dltA (%)
D-Alanylation
(%)
SA113 100 1.4 100 100
graRS::erm 8 100 13 53.3
a
dltA::spc nd nd 0 0
Unless noted otherwise, values represent the mean of three independent RT-PCRs.
aThe value represents one of three independent experiments.
nd, not determined.
doi:10.1371/journal.ppat.0030102.t003
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Lysozyme Resistance in Staphylococcus aureusan antagonist to Rot, as it up-regulates exoproteins and
down-regulates cell surface proteins, including the regulator
SarS. We found that Rot and MgrA regulate some of the
GraRS-controlled genes in the same direction. For these few
genes we do not know whether their up- or down-regulation
is directly affected by GraRS or indirectly via up-regulation of
Rot and MgrA, respectively. Moreover, there are some genes
that were regulated in opposite directions (Figure 6, boxed
genes). Interestingly, GraRS up-regulates both regulators, Rot
3.8- and MgrA 3.1-fold. GraRS controls many genes involved
in cell wall synthesis and transport (57 genes). Among the
transporters are the EssA and EssC proteins, involved in
transport of the virulence factor EsxA, oligopeptide transport
system (OppB), or NorB, which encodes the Blt-like protein
that is an efﬂux pump involved in multidrug resistance, all of
which are up-regulated by GraRS. Interestingly, smpC, which
encodes a membrane-spanning protein with unknown trans-
port functions, is the only gene that is increased by all four
regulators (GraRS, Rot, MgrA, and ArlRS). The gene which
had the highest (23.3-fold) up-regulation by GraRS was
Table 4. MIC Values of SA113 and Various Mutants
Strains Lysozyme Polymyxin B Gallidermin
lg/ml lM lg/ml lM lg/ml lM
SA113 .50,000 3,470 350 252.5 9 4.1
graRS::erm .50,000 3,470 20 14.4 2.5 1.14
oatA::kan 10,000 694 350 252.5 9 4.1
oatA::kan/graRS::erm 600 41.6 25 18 3 1.36
dltA::spc 2,000 138.8 10 7.2 1.2 0.55
oatA::kan/dltA::spc 30 2.08 10 7.2 1.2 0.55
graRS::erm (pTXgraRS) .50,000 3,470 .800 577.2 9 4.1
SA113 (pTXgraRS) .50,000 3,470 .500 360.8 9 4.1
The results represent the mean of three to five independent serial dilution experiments;
cells were grown in Basic Medium without glucose but with 0.5% xylose as an inductor.
doi:10.1371/journal.ppat.0030102.t004
Figure 5. Susceptibility of S. aureus graRS Mutant to Mutanolysin,
Mutanolysin and LP9 or Lysozyme, and Polymyxin B
(A) graRS mutant: control (*); mutanolysin (Mut) (100 lg/ml [4.35 lM])
( ); Mut (100 lg/ml) and LP9 (200 lg/ml) (3 j); Mut (50 lg/ml [2.18 lM])
and Lys (300 lg/ml) (3).
(B) graRS mutant: control (*); polymyxin B (PMB) (20 lg/ml) ( ).
(C) graRS subculture of 5B: control (&); PMB (20 lg/ml) (&).
Cells were grown in BM at 37 8C. OD578nm was measured hourly for the
first 8 h and after 24 h. Cationic agents were added in the exponential
growth phase at OD578nm 1.0 as indicated by arrow.
doi:10.1371/journal.ppat.0030102.g005
Figure 6. Interplay of GraRS–TCS with Other Global Regulators
Of the 248 genes regulated by GraRS, 115 genes are up-regulated and 133 genes are down-regulated. GraRS also upregulates the global regulators Rot
and Mgr (both are homologs of SarA). Genes that are controlled by both GraRS and Rot or GraRS and MgrA are boxed. Example genes that are
exclusively controlled by GraRS are circled.
doi:10.1371/journal.ppat.0030102.g006
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Lysozyme Resistance in Staphylococcus aureusSA1793, which encodes a hypothetical protein with a phage-
related function. Many of the down-regulated genes are
involved in RNA and amino acid synthesis or glycolysis. lrgA,
which encodes a holin-like protein with murein hydrolase
activity, is also down-regulated by GraRS but up-regulated by
ArlRS and MgrA. Most of the genes are exclusively regulated
by GraRS, such as ica, pur, mgrA, sirA,C, atlA, aaa, dnaJ,K, grpE,
and vraF,G. These results illustrate that there is a distinct
cross-regulation between GraRS, ArlRS, Rot, MgrA, and
probably some other global regulators.
GraRS is not only important for resistance to glycopep-
tides, lysozyme, and other CAMPs. Our data suggest that
GraRS also has an intermediate role between other global
regulators (Agr, MgrA, Rot, and SarA), as GraRS up-regulates
both adhesins as well as exoproteins and toxins (e.g., hlb,
hlgA,B, lukM,F, geh). GraRS is possibly involved in the
establishment of persistent infections by the up-regulation
of colonization factors (e.g., ica, atl, aaa, ﬁb, sirA, sirC, sdrC,
sdrE), factors involved in resistance to CAMPs (dlt), factors
involved in intermediary vancomycin resistance (vraF,G, as
mentioned above), and factors involved in bioﬁlm formation
(e.g., dlt, atl, ica). It would be interesting to study the graRS
mutant in an animal model for chronic infection.
Materials and Methods
Bacterial strains and plasmids. All of the strains and plasmids that
were used are listed in Table 5. Bacteria were grown in Basic Medium
(BM) (1% tryptone; Gibco BRL Life-Technologies, http://www.
invitrogen.com/), 0.5% yeast extract (Gibco BRL), 0.5% NaCl, 0.1%
K2HPO4, 0.1% glucose, or 0.5% xylose).
Transposon mutagenesis. Transposon mutagenesis was carried out
in the DoatA::kan mutant using the temperature-sensitive plasmid
pTV1ts and was performed as described by Bera et al. [10].
Construction of plasmids, homologous recombination, and trans-
duction. Was performed as described by Bera et al. [10]. The PCR
products, up- and downstream of graRS (SA0614/15) (U0614/15Kpn:
TGATATAGGTACCTAATTGTTTACTAGCCGACG, U0614/15Sma:
ATTTGTCCCGGGTTCTAGTAGTATTTGCATCC, D0614/15Sal:
GGCCGTGTCGACTTTGTCATTTTAAACATGCG, and D0614/
15Nhe: ATTGCTAGCTTGGCATAACTTGCTGCAACAGG), were
cloned into the polylinker of the pBT2 vector ﬂanking the ermB
antibiotic cassette. Complementation of the graRS deletion mutant
was obtained by cloning the graRS genes (1,912 bp) (C0614/15Bam:
AATGATGGATCCTGGCTTTGAAGTTGACTGCC, and C0614/
15Eco: AGCGCGAATTCATTTCCTTTAGGCTTTGGCAC) into the
xylose-inducible vector pTX15 in S. carnosus TM300. The oatA::kan/
dltA::spc double mutant was created by bacteriophage /11-mediated
transduction of the oatA::kan knockout into the dltA::spc deletion
mutant.
Effects of cationic agents on exponential growth. Overnight
cultures were diluted to an OD578nm of 0.1 in 50 ml of BM and the
cultures were incubated with shaking at 37 8C. OD was determined
every hour. Ten milliliters of each culture were transferred into a new
100-ml ﬂask when the cultures reached an OD578nm of nearly 1.0.
Then, cationic agents, such as hen egg-white lysozyme and human
lysozyme (Sigma-Aldrich, http://www.sigmaaldrich.com/), LP9 (a lyso-
zyme-derived 9-aa peptide, 107R-A-W-V-A-W-R-N-R115–NH2) (EMC,
http://www.microcollections.de/), polymyxin B (Sigma-Aldrich), galli-
dermin (Genmedics, http://www.genmedics.com/), or mutanolysin
(Sigma), were added. Lysozyme was inactivated by heating for 1 h at
100 8C and placed on ice. The OD578nm of all cultures was measured
hourly up to 7–8 h and after 24 h.
MIC assay. The overnight cultures were diluted in BM with 0.5%
xylose to a concentration of 0.5 3 10
6 CFU per ml and aliquoted in
0.5-ml samples, and cationic agents in different concentrations were
added. The cultures were incubated with shaking at 37 8C for 20–24 h
and MIC was determined.
Bioﬁlm assay. An overnight culture was diluted 1:200 in fresh TSB
with 0.5% glucose, and 200 ll were ﬁlled into microtiter plates and
incubated for 20–24 h at 37 8C without shaking. The supernatant was
removed and the plate was washed two times with PBS (pH 7.4). The
plate was dried and the cells were colored with 0.1% safranine.
Isolation of PG. One liter of BM was inoculated with an overnight
culture of the WT SA113 or the mutants. Strains were grown for 12 h
with shaking at 37 8C. Cells were centrifuged, washed two times with
cold 0.9% NaCl, diluted in 0.9% NaCl, and boiled for 20 min. After
the cells were chilled on ice, they were again centrifuged and washed
twice with 0.9% NaCl. The cells were disrupted in a mechanical
grinding device using glass beads 150–212 lm (Sigma-Aldrich) at 4 8C,
centrifuged and washed two times with cold H2Obidest, boiled for 30
min in 2% SDS to remove noncovalently bound proteins, and washed
four times with H2Obidest. The cell wall fragments were diluted in 0.1
M Tris/HCl (pH 6.8) and incubated with 0.5 mg/ml trypsin for 16 h at
37 8C to degrade cell-bound proteins. After centrifugation and
washing with water, the PG was lyophilized.
Turbidometric assay of PG. For analyzing the susceptibility of PG
to lysozyme, we used a modiﬁed method turbidometric assay as
described by Clarke [42]. The PG of the WT SA113 and the mutants
were sonicated and diluted to 0.5 mg in 1 ml of 80 mM PBS (pH 6.4).
After the addition of 300 lg lysozyme per ml, the decrease in optical
density was monitored at the beginning (0 h) and after 4 h at OD660nm
and calculated as percentages.
Table 5. List of Strains and Plasmids
Strain or Plasmid Comment Reference or Source
S. aureus RN4220 Mutant strain of 8325–4, accept foreign DNA Kreiswirth [46]
S. aureus SA113 Mutant strain of 8325, with an agr
  background and 11-bp deletion in rsbU Iordanescu [47]
S. aureus SA113DoatA Mutant of SA113 (DoatA::kan) Bera [10]
S. aureus SA113DdltA Mutant of SA113 (DdltA::spc) Peschel [26]
S. aureus SA113DgraRS Mutant of SA113 (DgraRS::erm) This study
S. aureus SA113DoatA/DgraRS oatAa n dgraRS double mutant of SA113 (DoatA::kan/DgraRS::erm) This study
S. aureus SA113DoatA/DdltA oatAa n ddltA double mutant of SA113 (DoatA::kan/DdltA::spc) This study
S. aureus SA113DgraRS þ (pTXgraRS) DgraRS::erm and pTX15 containing xylose inducible graRS genes This study
S. aureus SA113 þ (pTXgraRS) SA113 and pTX15 containing xylose inducible graRS genes This study
S. carnosus TM300 Host strain for cloning vector pTX15 Go ¨tz [48]
Escherichia coli Dh5a Host strain for cloning vector pBT2 Hanahan [49]
pBT2 Temperature-sensitive E. coli–S. aureus shuttle vector Bru ¨ckner [50]
pBTudgraRS pBT2 containing up- and downstream region of graRS and ermB cassette This study
pTX15 Xylose-inducing vector for complementation Peschel [51]
pTXgraRS pTX15 containing xylose-inducible graRS genes This study
pTV1ts Vector for transposon (Tn917) mutagenesis Youngman [52]
doi:10.1371/journal.ppat.0030102.t005
PLoS Pathogens | www.plospathogens.org July 2007 | Volume 3 | Issue 7 | e102 0992
Lysozyme Resistance in Staphylococcus aureusQuantiﬁcation of D-alanylation of TA by HPLC. S. aureus strains
were grown in BM with 0.25% glucose overnight, centrifuged, washed
three times, and resuspended in ammonium acetate buffer (20 mM
[pH 6.0]). The OD600nm was adjusted to 30. Aliquots (1 ml) were heat-
inactivated by incubation at 99 8C for 10 min and centrifuged, and
pellets were dried. After incubation at 37 8C for 1 h with 100 ll of 0.1
N NaOH, 100 ll of 0.1 N HCl were added for neutralization and
samples were dried. For derivatization, 100 ll of triethylamine and
100 ll of Marfey’s reagent (1-ﬂuoro-2,4-dinitrophenyl-5-L-alanine
amide; Sigma) (10 mM) were added. After incubation at 40 8C for 1 h,
samples were dried and resuspended in DMSO:H2O (1:1). Quantiﬁ-
cation of D-alanine was performed by HPLC as previously described
[43].
RNA isolation and real-time RT-PCR. SA113 and the graRS
deletion mutant were cultivated in 50 ml of BM and harvested at
mid-exponential growth phase. Before RNA isolation, two volumes of
RNAprotect bacteria reagent (Qiagen, http://www.qiagen.com/) were
added to 10 ml of culture and centrifuged. The cells were lysed by the
addition of 50 lg/ml of lysostaphin (0.5 mg/ml) (Genmedics) in TE
buffer and total RNA was isolated using the RNeasy Mini Kit
(Qiagen). Contaminating DNA was degraded with the DNase Kit
(Ambion, http://www.ambion.com/) according to the manufacturer’s
instructions. LightCycler RT-PCR was carried out using the Light-
Cycler RNA ampliﬁcation Kit SYBR Green I or with the LightCycler
RNA ampliﬁcation kit for hybridization probes (Roche Biochemicals,
http://www.roche.com/). The internal control gyr was quantiﬁed using
10-fold serial dilutions (10
4 to 10
8 copies/ll) of a speciﬁc RNA
standard using oligonucleotides speciﬁc for gyr (gyr297F:
TTAGTGTGGGAAATTGTCGATAAT and gyr574R: AGTCTTGTGA-
CAATGCGTT TACA), dltA (dltA1: TGGCGTTGAAAGACTAGGC and
dltA2: TTACGAACTCAGACTGGCG), rot (rot1: TTCAGCGAGATT-
GAAAGCG and rot2: GTTGCTCTACTTGCAATGG) or ureC (ureC1:
GATATCATTGCCGCTGAAGG and ureC2: AAAGCA-
GATGGTGTTGCACC) as described [44]. Standard curves for dltA
and rot were generated using 5-fold serial dilutions of WT SA113 RNA
or for ureC of the graRS mutant RNA. Differences between WT and
the graRS mutant were determined by n-fold change and calculated as
a percentage of the mRNA product. The speciﬁcity of the PCR was
veriﬁed by size determination of the amplicons by agarose gel
electrophoresis. To check for DNA contamination, each sample was
subjected to PCR by using the LightCycler DNA ampliﬁcation kit
SYBR Green I (Roche Biochemicals). In none of the cases an
ampliﬁcation product was detectable.
Transcriptome analysis. Transcriptome analysis was carried out as
described by the microarray manufacturer Scienion (http://www.
scienion.de/) and Resch et al. [45]. cDNA was synthesized from
isolated RNA (1 lg) during mid-exponential growth (4 h) derived
from WT SA113 (labeled in green with Cy3 [532 nm]) or from the
graRS mutant (labeled in red with Cy5 [635 nm]). cDNAs from WT
and the graRS mutant were pooled and hybridized on four DNA
microarrays. Scienion performed DNA transcriptome analysis by
comparing the intensity of each Cy3-labeled gene of the WT with the
intensity of each Cy5-labeled gene of the graRS mutant as a ratio of
the medians (532/635). The threshold was set at a 2-fold difference in
gene expression. Genes whose RNA level was higher in WT (2.0 and
more) were categorized as being positively regulated by GraRS. In
contrast, genes that had higher RNA levels (2.0 and more) in the graRS
mutant were described as being negatively regulated by GraRS. The
signiﬁcance of differences (n-fold) in gene expression was calculated
by One-Sample t-Test-Benjamini–Hochberg (Adv); results ,0.051 are
signiﬁcant, and some genes from Tables 1 and 2 are higher than 0.05.
Supporting Information
Dataset S1. GraRS-Regulated Genes
Found at doi:10.1371/journal.ppat.0030102.sd001 (36 KB XLS).
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